Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

18th May 2026 Uncategorised 0

Already tracking $5 billion in annual sales, Enhertu has secured two new FDA approvals for treating early breast cancer. But while arriving nearly two months early, the adjuvant label comes with a catch.

More: Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Source: fierce